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Abstract
Background: Before the genome-wide association (GWA) era, many hypothesis-driven candidate gene association studies
were performed that tested whether DNA variants in genes that had been selected based on prior knowledge about
migraine pathophysiology were associated with migraine. Most studies involved small sample sets without robust rep-
lication, thereby making the risk of false-positive findings high. Genome-wide marker data of thousands of migraine
patients and controls from the International Headache Genetics Consortium provide a unique opportunity to re-evaluate
key findings from candidate gene association studies (and other non-GWA genetic studies) in a much larger data set.
Methods: We selected 21 genes from published candidate gene association studies and six additional genes from other
non-GWA genetic studies in migraine. Single nucleotide polymorphisms (SNPs) in these genes, as well as in the regions
500 kb up- and downstream, were inspected in IHGC GWAS data from 5175 clinic-based migraine patients with and
without aura and 13,972 controls.
Results: None of the SNPs in or near the 27 genes, including the SNPs that were previously found to be associated with
migraine, reached the Bonferroni-corrected significance threshold; neither when analyzing all migraine patients together,
nor when analyzing the migraine with and without aura patients or males and females separately.
Conclusion: The available migraine GWAS data provide no clear evidence for involvement of the previously reported
most promising candidate genes in migraine.
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Disease susceptibility for common disorders, including
migraine, is thought to be conferred by a combination
of environmental factors and genetic factors that are
either common (i.e. with a minor allele frequency
(MAF) larger than 5% in the population) or rare. In
the past decades, many genetic association studies have
been performed by testing DNA variants in dozens of
candidate genes in order to identify genetic factors for
migraine (1,2). Genes were selected based on the
hypothesis that the respective pathway was implicated
in migraine pathophysiology; e.g. genes that play a role
in serotonin and dopamine pathways (3). The majority
of the studies investigated only a single or a limited
number of DNA variants per gene and therefore had
a low a priori likelihood of targeting the correct variant
that confers disease susceptibility. Moreover, rather
low numbers of cases and controls (rarely more than
300 per group) were studied, resulting in limited statis-
tical power to evaluate their association. For the major-
ity of the associations no replication of the findings in
independent cohorts was provided (for review, see de
Vries et al. (1)). Consequently, many of the associations
may in fact represent false-positive findings. Similar
experiences have been observed in other common dis-
eases (4–6).
Over the last few years, genome-wide association
studies (GWAS) have become the state-of-the-art
approach to identify genetic factors involved in
common disorders. Unlike candidate gene association
studies that are hypothesis driven, GWAS are hypoth-
esis free and hypothesis generating in nature. Typically
they involve large cohorts of at least several thousand
patients and controls and test the association with dis-
ease of hundreds of thousands of single nucleotide
polymorphisms (SNPs) distributed over the genome
(7). Importantly, initial association findings are
always scrutinized by follow-up testing in multiple inde-
pendent replication cohorts. Therefore, the GWAS
approach is less susceptible to false-positive results
and more powerful than candidate gene association
studies. Two GWA studies that investigated large num-
bers of migraine cases from clinic-based cohorts and
controls have been published (8,9). One study investi-
gated migraine with aura (MA) (with 2731 cases and
10,747 controls) and revealed a single genome-wide sig-
nificant migraine susceptibility locus on chromosome
8q22.1 that pinpointed the MTDH gene as the possible
disease-causing gene in this region (8). The other study
investigated migraine without aura (MO) (with 2326
cases and 4580 controls) and yielded four additional
migraine susceptibility loci on 1q22, 3p24, 6p24 and
9q33 presenting evidence for involvement of the
MEF2D, TGFBR2, PHACTR1 and ASTN2 genes,
respectively (9). The latter study also confirmed genetic
associations of SNPs in the TRPM8 and LRP1 genes
(2q37 and 12q13, respectively) that had previously been
identified as migraine susceptibility loci in a popula-
tion-based GWA study (with 5122 cases and 18,108
controls) (10). A recent large meta-analysis (with
23,285 cases and 95,425 controls) that studied patients
from clinic-based as well as population-based cohorts
confirmed these loci and provided evidence for five add-
itional migraine susceptibility loci (11). Notably, none
of these genome-wide significant gene loci overlapped
with genes that had been selected for candidate gene
association studies in migraine.
The availability of GWAS data provides a unique
opportunity to re-evaluate key findings from previous
genetic studies in a much larger data set. We investi-
gated 27 genes. Twenty-one genes were previously
reported to be associated with migraine in candidate
genes-based association studies. Three genes had been
identified by positional cloning studies in families with
familial hemiplegic migraine (FHM), a monogenic sub-
type of MA (12–14). Three genes came from direct
sequencing of candidate genes in families and patients
with monogenic migraine or common migraine (15–17).
As the majority of the original studies
investigated migraine patients who had been collected
via specialized headache centers (i.e. patients
who are clinic-based), we restricted our investigations
to GWAS data of clinic-based migraine patients only
(8,9,11).
Materials and methods
Selection of candidate genes for re-evaluation in
the International Headache Genetics Consortium
(IHGC) GWA data set
Genes were selected for re-evaluation in the IHGC
GWAS data set based on the results of a literature
search of candidate gene association studies in
migraine. We included studies that had investigated at
least 300 migraine patients and 300 controls of
Caucasian origin. From these studies, we selected
only those genes for which at least nominally signifi-
cant, uncorrected p values (p< 0.05) were reported
for one or more SNPs (see list of genes in
Table 1). In addition, we selected genes from non-
GWA genetic studies of migraine, namely the three
FHM genes (CACNA1A (12), ATP1A2 (13) and
SCN1A (14)) and three genes in which possibly
causal mutations had been identified by a candidate
gene sequencing approach, i.e. SLC1A3 (which
encodes the EAAT1 glutamate transporter) (15),
SLC4A4 (twhich encodes the NbCe1 protein) (16),
and KCNK18 (which encodes the TRESK protein)
(17) (Table 2).
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GWAS data sets
GWAS data of 2849 MA patients and 2326 MO
patients from five clinic-based cohorts were collected
via specialized headache centers in Finland, the
Netherlands, and Germany (8,9,11). Migraine diag-
noses were based on a combination of questionnaires
and/or individual interviews according to the
International Classification of Headache Disorders,
second edition (ICHD-II) guidelines (38) (Table 3).
Since the patients of nearly all candidate gene associ-
ation studies came from clinic-based cohorts, we chose
to investigate GWAS data only from clinic-based
cohorts and not from population-based cohorts. An
additional reason for including only clinic-based
cohorts is that phenotypic information is less detailed
and/or accurate in population-based cohorts, which
would probably increase clinical and genetic heterogen-
eity. In all GWAS samples, standard quality control
measures were applied; SNPs with call rates <97%,
Table 1. Summary of candidate gene association studies performed for migraine that reported at least nominal evidence for
















677T: NS (p¼ 0.017/)
677T:  (p< 0.006/NS)
677T: NS (p¼ 0.0005/NS)
677T: NS (p¼ 0.02/)
Lea et al. 2004 (18)
Scher et al. 2006 (19)
Rubino et al. 2009 (20)





1021T: p¼ 0.004 (p¼ 0.011/NS)
rs2097629:  (p¼ 0.01/)
Fernandez et al. 2009 (22)
Todt et al. 2009 (23)





rs7131056:  (p¼ 0.006/)
rs2283265: p¼ 0.0030 (p¼ 0.037/p¼ 0.0081)
Todt et al. 2009 (23)
Corominas et al. 2009 (24)
DRD3 543 (318/225) 561 rs3732790: p¼ 0.0033 (/) Corominas et al. 2009 (24)
SLC6A3 543 (318/225) 561 rs40184:  (p¼ 0.03/) Todt et al. 2009 (23)
TH 543 (318/225) 561 rs2070762: p¼ 0.0035 (NS/P¼ 0.036) Corominas et al. 2009 (24)
EDNRA 850 (850/) 890 rs2048894: – (p¼ 0.015/–)
rs5334: – (p¼ 0.046/–)
Tikka-Kleemola et al. 2009 (25)
EDNRB 850 (850/–) 890 rs2329047:  (0.035/) Tikka-Kleemola et al. 2009 (25)
STX1A 569 (407/129) 720 rs941298: p¼ 0.004(NS/p¼ 0.008) Tropeano et al. 2012 (26)
TRPV1 1040 (490/650) 1037 rs222741: p¼ 0.03 (NS/NS) Carreno et al. 2012 (27)
TRPV3 1040 (490/650) 1037 rs7217270: NS (p¼ 0.02/NS) Carreno et al. 2012 (27)











rs1801132: p¼ 0.03 (p¼ 0.045/NS)
Colson et al. 2004 (29)
Kaunisto et al. 2006 (30)
Oterino et al. 2008 (28)
ESR2 356 (198/158) 374 2039G: NS (p¼ 0.01/NS) Oterino et al. 2008 (28)
PGR 509 (371/138) 454 PROGINS ins: p¼ 0.02 (NS/p¼ 0.008) Colson et al. 2005 (31)
TNFA 299 (38/261) 306 308G: p< 0.001 (NS/p< 0.001) Rainero et al. 2004 (32)
SLC6A4 546 (257/289) 770 STin2: p¼ 0.002 (NS/NS) Schürks et al. 2010 (33)
TPH2 503 (214/289) 515 Haplotype block with five SNPs:
p¼ 0.04 (p¼ 0.4/p¼ 0.006)
Jung et al. 2010 (34)





c.2946-713A: NS (p¼ 0.002/NS)
c.2842þ 1451A: NS (p¼ 0.007/NS)
c.3255T: NS (p¼ 0.008/NS)
c.2842þ 1451T:  (p¼ 0.005/)
McCarthy et al. 2001 (36)
Netzer et al. 2008 (37)
MA: migraine with aura; MO: migraine without migraine; NS: not significant; : not tested/not available; SNP: single nucleotide polymorphism;
Ins: insertion; Del: deletion; VNTR: variable number of tandem repeats. aNumber of cases and bp values are given for all migraine cases combined or,
when specified between brackets, for migraine with aura cases only and/or migraine without aura cases only.
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MAF <1% and/or excessive deviation from Hardy-
Weinberg equilibrium (with p< 106) in either cases
or controls were excluded. Individuals with a genotyp-
ing rate <97% were excluded from the analyses (for
more details, see Anttila et al. (11)).
Genome-wide marker data from 13,972 individuals
from several pre-existing non-overlapping control
cohorts that were population-matched to the cases
were used as controls. The majority of the control
cohorts were unselected for migraine status, implicating
that they are expected to contain cases at the same fre-
quency as the general population (Table 3). In the
meta-analysis, SNPs missing from one of the studies,
those with a MAF< 1%, and/or those showing excess
heterogeneity (I2> 0.75) were excluded.
Power calculation and significance threshold
Data for the selected genes were extracted from the
existing GWAS data from an interval containing the
candidate gene and the flanking region 500 kb in each
direction, to have a reasonable chance of covering pos-
sible regulatory effects for the targeted genes. The
threshold for evaluating the significance of SNPs
located in the tested gene regions was 2.19 106,
based on a Bonferroni correction for the number of
unique SNPs that were tested (0.05/22,774). Our
GWAS sample (5175 cases and 13,972 controls) has
99% power to detect association with an SNP under
the assumption of an allele frequency (AF) of at least
0.05 and a relative risk of 1.5 or higher (allelic test,
Genetic Power Calculator (http://pngu.mgh.harvar-
d.edu/purcell/gpc) (19)). These thresholds are in line
with published candidate gene association studies. On a
more stringent level, we have 84% power to detect a
variant with a relative risk of 1.4. See Supplemental
Table 1 for power calculations at a range of different
allele frequencies (0.05–0.4) and relative risks (1.15–
1.5).
Effect size estimation
We used the Genetic Power Calculator to estimate the
genotype frequencies for a marker with similar MAF
and odds ratio (OR) as the MTHFR C677T risk allele,
while assuming a disease prevalence of 12%, and using
the sample size of the current study (5175 cases and
13,972 controls). A chi-square test for the resulting
genotype frequencies was converted to a p value using
a two-degree of freedom (df) chi-square test.
Results
We used GWAS data of clinic-based migraine patients
(8,9,11) to re-evaluate 21 genes from migraine candi-
date gene association studies that had analyzed at
least 300 migraine cases and controls and yielded asso-
ciations of at least nominal p values (Table 1). Six
additional genes were included that came from other
non-GWA studies, i.e. either candidate gene sequencing
Table 2. Migraine candidate genes from family studies.
Gene Relation to migraine Reference
CACNA1A (FHM1) A linkage study identified CACNA1A as the first FHM gene.
CACNA1A encodes the a1 pore-forming subunit of CaV2.1 cal-
cium channels.
Ophoff et al. 1996 (12)
ATP1A2 (FHM2) A linkage study identified ATP1A2 as the second FHM gene. ATP1A2
encodes the a2 subunit of sodium-potassium pumps.
De Fusco et al. 2003 (13)
SCN1A (FHM3) A linkage study identified SCN1A as the third FHM gene. SCN1A
encodes the a1 subunit of neuronal NaV1.1 sodium channels.
Dichgans et al. 2005 (14)
SLC1A3/EAAT1 A mutation in a single case with SHM that was identified through
sequencing of the coding exons of SLC1A3 and presented first
evidence for SLC1A3 as an SHM gene. SLC1A3 encodes the
EAAT1 glutamate transporter.
Freilinger et al. 2010 (15)
SLC4A4/NBCe1 Homozygous mutations in SLC4A4 were reported in two sisters
with reported hemiplegic migraine, in addition to proximal renal
tubular acidosis and ocular abnormalities, and presented first
evidence for SLC4A4 as a migraine gene. SLC4A4 encodes the
Naþ–NCO3 cotransporter NBCe1.
Suzuki et al. 2010 (16)
KCNK18/TRESK A mutation in KCNK18 in a single family with familiar migraine was
identified in a candidate gene sequencing approach and pre-
sented first evidence for KCNK18 as a migraine gene. KCNK18
encodes for the ion channel TRESK.
Lafrenière et al. 2010 (17)
FHM: familial hemiplegic migraine; SHM: sporadic hemiplegic migraine; MA: migraine with aura.



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































studies (KCNK18, SLC1A3, SLC4A4) in common
migraine and/or hemiplegic migraine or linkage studies
in FHM (CACNA1A, ATP1A2, SCN1A) (Table 2).
Within the 27 gene regions we investigated 22,774
SNPs for association with migraine, applying a signifi-
cance threshold for individual SNPs of 2.19 106.
None of the SNPs, including the specific SNPs
reported in the original publications (Supplemental
Table 2), surpassed the significance threshold (Table
4, Supplemental Information). When analyzing MA
and MO together, the best p value was seen for SNP
rs805287 (p¼ 1.08 104) that is located within the
surrounding region of the TNFA and LTA genes.
However, this SNP is located in a gene-dense region
over 130 kb downstream of both genes (Figure 1(a))
and lies within the major histocompatibility complex
locus, where overall levels of noise are higher because
of the complex linkage disequilibrium structure (49).
When analyzing MA and MO separately, for MA,
again the best p value was observed with an SNP
(rs630379; p¼ 9.68 106) at the border of the region
surrounding the TNFA and LTA genes (Supplemental
Information). For MO, the best p value was seen for an
SNP (rs13024246, p¼ 2.76 105) located in the FSHR
gene region (Figure 1(b)) but this SNP was located far
away from the originally selected gene. Only one gene
region, namely that of the DRD3 gene, showed a poten-
tially interesting peak (with best associated SNP
rs1486008, p¼ 2.88 104; OR¼ 1.19) within the pre-
viously implicated migraine gene (Figure 1(c)).
Although the chance of observing associations that
are gender-specific is limited, as the vast majority of the
migraine patients are women, we performed a gender-
specific analysis for the total migraine group. Analyzing
males and females separately did not reveal SNPs with
gender-specific signals surpassing the significance
threshold (Supplemental Table 3).
Discussion
For this study, we used the data of clinic-based GWA
cohorts from the IHGC (8,9,11) to re-evaluate key find-
ings from previously published candidate gene associ-
ation studies (and other genetic non-GWAS studies) in
migraine. Our study included GWAS data from 5175
migraine patients and 13,972 controls and shows no
significant association with migraine for any of the 27
genes (Table 4), despite the fact that our study had
sufficient power (>95%) to significantly detect genetic
association signals for variants with an MAF >0.05
and a relative risk >1.4, as commonly presumed in
the much smaller migraine candidate gene association
studies. Only a few single SNPs for some of the 27
selected gene regions showed moderate evidence of
association. Notably, none of the p values of the
SNPs reported in the original publications surpassed
the significance threshold (Supplemental Table 2), nor
translated to the originally reported effect sizes. For
example, the T-allele of the C677T polymorphism in
theMTHFR gene, which showed significant association
with migraine in various candidate gene association
studies, did not show up in our study. Assuming an
effect size of 1.5, which is in line with previously
reported effect sizes for this variant in migraine (18–
21, 50), and an MAF of 31% in the European popula-
tion (51), our study would have produced a p value
below 1.46 1063. However, the T-allele showed no
association with migraine in our study (p¼ 0.56 for
migraine; p¼ 0.51 for MA; p¼ 0.11 for MO); the
lowest observed p value in the MTHFR gene region
in our study was 7.18 104 for SNP rs11121783.
Also for the other SNPs of the originally reported asso-
ciations, our study should have produced low p values;
well below the set threshold of 2.19 106, if the
reported effect sizes would have replicated. These
poor replication results indicate the limited value of
small-scale genetic association studies at the single-gene
or single-marker level, and emphasize the importance
of using large, well-powered studies that are properly
designed. This finding is in line with a recent review that
supports the statistical observation that low power due
to small sample sizes not only decreases the chance to
detect a true effect, but also increases the chance that a
significant finding does not reflect a true effect (52).
Based on current knowledge of effect sizes of
common variants for many common diseases, the vast
majority of the candidate gene association studies in the
literature lacked sufficient power to detect an effect that
can be realistically expected for a common allele in a
common disorder like migraine. Therefore, the most
probable reason for the lack of replication is that the
results of the candidate gene association studies most
likely represent false-positive findings. Although we did
not show significant evidence for any of the genes pre-
viously implicated in common migraine as genetic
migraine risk factors, we cannot, however, exclude the
possibility that some of the previous findings are true-
positive findings reflecting effects specific to a particular
patient pool (such as individual families, in whom
alleles that are rare in the general population can pre-
dominate). Possible additional reasons that could
explain why we did not detect associations are that:
(1) rare variants that may play a role may not be cap-
tured, either in candidate gene association studies or
GWAS platforms, because of specific LD patterns
that are not sufficiently reflected in the surrounding
common markers; or (2) variants located in these can-
didate gene regions may play a role that have effect
sizes too low to be detected, even with the current
sample size, and will surface only with sample sizes
de Vries et al. 609
TNFA & LTA – ALL migraine
FSHR – MO
















































































































































31.4 31.6 31.8 32
Position on chr6 (Mb)
Position on chr2 (Mb)
115 115.2 115.4 115.6 115.8
















Figure 1. Regional association plot (generated using LocusZoom) for SNPs within the (a) TNFA and LTA gene region and their
association with migraine; (b) the FSHR gene region and their association with migraine without aura (MO); and (c) the DRD3 gene
region and their association with migraine. The plots show the chromosomal position (based on NCBI build 36) for the SNP in the
respective region against –log10 p values. The SNP with the highest association signal is represented as a purple diamond. Other SNPs
are color coded according to the extent of LD with that specific SNP. SNP: single nucleotide polymorphism; NCBI: National Center














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































de Vries et al. 611
on the order of several hundreds of thousands cases and
controls.
In conclusion, our analysis shows no evidence for the
involvement of any of the selected 27 genes in migraine
pathophysiology of common migraine. For future
studies, other approaches should be considered to iden-
tify migraine susceptibility genes. This finding is in line
with experiences of candidate gene association studies
in other common diseases (53).
Article highlights
. Re-evaluation of previously reported migraine candidate gene hits shows no evidence for involvement in
migraine pathology in a genome-wide association (GWA) data set.
. Small-scale genetic association studies lacking proper replication appear of limited value.
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Genetic association study of endothelin-1 and its recep-
tors EDNRA and EDNRB in migraine with aura.
Cephalalgia 2009; 29: 1224–1231.
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